• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Advantage Healthcare Holdings Appoints Dinak Nair as Chief Executive Officer

    9/25/24 11:19:00 AM ET
    $AHCO
    $LH
    Medical/Nursing Services
    Health Care
    Medical Specialities
    Health Care
    Get the next $AHCO alert in real time by email

    Advantage Healthcare Holdings ("Advantage" or the "Company"), a regional leader in providing patient-centered healthcare through managing and operating Comprehensive Outpatient Rehabilitation Facilities and Sleep Centers, announced that its Board of Directors has named Dinak (Dino) Nair as its Chief Executive Officer. Mr. Nair assumed leadership of the Company from the prior CEO, Ryan Tong, on September 1, 2024.

    Mr. Nair brings over 20 years of business experience, with more than a decade as a mission-driven leader growing businesses in the healthcare market, especially in homecare, home medical equipment, diagnostic laboratory, and health system partnerships. Mr. Nair most recently served as Vice President, General Manager of the Health Systems Operating Division at Labcorp (NYSE:LH). Previously, Mr. Nair served as Senior Vice President at Thrive Skilled Pediatric Care, and as Vice President of Operations at AdaptHealth (NASDAQ:AHCO). Mr. Nair graduated from the prestigious Bronx High School of Science, holds a B.A. in Business Administration from Sacramento International University, and earned his MBA in Public Accounting from the Tobin College of Business at Saint John's University.

    "We are thrilled to welcome Dino to Advantage," said Timothy Bovard, Chairperson of the Board of Advantage. "Our Board conducted an extensive search and Dino stood out as the ideal fit for us. With his extensive experience in healthcare, particularly sleep and pulmonary therapy, we are confident Dino has the skills and exemplary leadership to lead Advantage as it looks to grow and expand its ability to improve outcomes for more patients through personalized care."

    "I am excited to join the Advantage family, and lead the Company in our continued growth, building on the positive energy that has been established," Mr. Nair said. "I look forward to collaborating closely with our team to execute initiatives to drive improved patient outcomes through greater access, while delivering value to our customers and stakeholders."

    "On behalf of the Board of Directors, we would like to thank Ryan for his leadership," said Mr. Bovard. "He led the Company through some challenging times and is delivering a business poised for growth to Dino."

    About Advantage Healthcare Holdings

    Advantage is a regional leader in managing and operating Comprehensive Outpatient Rehabilitation Facilities and Sleep Centers (Sleep Labs). The Company provides a wide array of services, including Physical Therapy, Occupational Therapy, Pulmonary Rehabilitation, In-Lab Sleep Testing, Home Sleep Testing, and Remote Patient Monitoring. Advantage also runs an Accredited Sleep Technologist Education Program (A-STEP).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240925779746/en/

    Get the next $AHCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHCO
    $LH

    CompanyDatePrice TargetRatingAnalyst
    Labcorp Holdings Inc.
    $LH
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    Labcorp Holdings Inc.
    $LH
    4/2/2025$276.00Buy
    Redburn Atlantic
    Labcorp Holdings Inc.
    $LH
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    Labcorp Holdings Inc.
    $LH
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    Labcorp Holdings Inc.
    $LH
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    Labcorp Holdings Inc.
    $LH
    10/30/2024Hold → Buy
    HSBC Securities
    Labcorp Holdings Inc.
    $LH
    10/1/2024$235.00Neutral
    Piper Sandler
    Labcorp Holdings Inc.
    $LH
    3/25/2024$250.00Hold → Buy
    Argus
    More analyst ratings

    $AHCO
    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Sampson John H

    3 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/11/26 9:04:22 AM ET
    $LH
    Medical Specialities
    Health Care

    Chief Financial Officer, EVP Wang Julia Aijun converted options into 893 shares and covered exercise/tax liability with 254 shares, increasing direct ownership by 113% to 1,202 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/10/26 3:34:20 PM ET
    $LH
    Medical Specialities
    Health Care

    EVP, Pres of ED, CMO & CSO Caveney Brian J converted options into 1,298 shares and covered exercise/tax liability with 389 shares, increasing direct ownership by 3% to 31,078 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/10/26 3:18:03 PM ET
    $LH
    Medical Specialities
    Health Care

    $AHCO
    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

    7/10/25 9:03:30 AM ET
    $LH
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

    Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

    4/2/25 8:50:29 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. upgraded by Citigroup with a new price target

    Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

    3/4/25 7:36:42 AM ET
    $LH
    Medical Specialities
    Health Care

    $AHCO
    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

    Elecsys® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathologyNow available nationwide in primary care settings for patients aged 55 and older experiencing symptoms of cognitive declineExpands Labcorp's comprehensive portfolio of Alzheimer's disease blood tests across both primary and specialty care settingsBURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessme

    2/11/26 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    AdaptHealth Corp. Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its fourth quarter and full year 2025 financial results before the opening of the financial markets on Tuesday, February 24, 2026. Management will host a teleconference at 8:30 a.m. ET to discuss the results and business activities with analysts and investors. Interested parties may participate in the call by dialing: (833) 316-2483 (Domestic) or (785) 838-9284 (International) When prompted, reference Conference ID: AHCO4Q25 Webcast registration: Clic

    2/3/26 4:05:00 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    $LH
    SEC Filings

    View All

    SEC Form 144 filed by Labcorp Holdings Inc.

    144 - LABCORP HOLDINGS INC. (0000920148) (Subject)

    2/9/26 1:30:58 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    2/9/26 8:34:53 AM ET
    $LH
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by AdaptHealth Corp.

    SCHEDULE 13G/A - AdaptHealth Corp. (0001725255) (Subject)

    2/5/26 1:16:32 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    $LH
    Financials

    Live finance-specific insights

    View All

    AdaptHealth Corp. Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its fourth quarter and full year 2025 financial results before the opening of the financial markets on Tuesday, February 24, 2026. Management will host a teleconference at 8:30 a.m. ET to discuss the results and business activities with analysts and investors. Interested parties may participate in the call by dialing: (833) 316-2483 (Domestic) or (785) 838-9284 (International) When prompted, reference Conference ID: AHCO4Q25 Webcast registration: Clic

    2/3/26 4:05:00 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

    BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

    1/15/26 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and c

    1/14/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $AHCO
    $LH
    Leadership Updates

    Live Leadership Updates

    View All

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Appoints Victor Bulto to Board of Directors

    Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leadin

    11/24/25 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services

    $AHCO
    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AdaptHealth Corp.

    SC 13G/A - AdaptHealth Corp. (0001725255) (Subject)

    11/14/24 9:03:31 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by AdaptHealth Corp.

    SC 13G - AdaptHealth Corp. (0001725255) (Subject)

    11/13/24 9:30:46 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by AdaptHealth Corp.

    SC 13G/A - AdaptHealth Corp. (0001725255) (Subject)

    11/12/24 1:30:20 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care